Long-Term Omeprazole Side Effects and Management

Established Adverse Effects with Strong Evidence

The American College of Gastroenterology recommends careful monitoring for signs of renal deterioration during omeprazole treatment, particularly in male patients, due to the risk of acute tubulointerstitial nephritis 2
Meta-analysis shows a 71% higher risk of hypomagnesemia (adjusted OR: 1.71; 95% CI: 1.33, 2.19) in patients taking PPIs for at least 3 months 1
Reduced gastric acid barrier increases susceptibility to gastroenteritis and other enteric infections, with the American Academy of Pediatrics noting this risk in pediatric populations 1
PPIs increase the risk of community-acquired pneumonia, but not hospital-acquired pneumonia, with infants potentially at increased risk of lower respiratory tract infections 1
Rebound acid hypersecretion is a common physiological response after discontinuation of long-term PPI therapy, lasting 2-6 months and representing secondary hypergastrinemia 1
Enterochromaffin-Like (ECL) cell hyperplasia is demonstrated in up to 50% of patients receiving PPIs for >2.5 years, considered a benign histologic change with no evidence of dysplasia or neoplasia in clinical trials 1

Some observational studies suggest an increased cardiovascular disease risk with long-term PPI use, but large randomized controlled trials, including the COMPASS trial, found no differences in cardiovascular event rates between PPI and placebo groups 1
Omeprazole may decrease the platelet inhibitory effect of clopidogrel through CYP2C19 competition, with the FDA requiring a statement on clopidogrel labels discouraging concomitant omeprazole administration 3, 4
Meta-analysis of 24 observational studies found a 20% greater risk of hip fracture (RR: 1.20; 95% CI: 1.14, 1.28) in long-term PPI users, but large RCTs, including the COMPASS trial, found no differences in fracture rates between PPI and placebo 1

Patients with definitive indications, such as Barrett's esophagus, severe erosive esophagitis, eosinophilic esophagitis with PPI response, idiopathic pulmonary fibrosis, high-risk NSAID/aspirin users requiring gastroprotection, and secondary prevention of gastric/duodenal ulcers, should not discontinue omeprazole based on concerns about potential adverse events 1, 3
All patients without definitive indication for chronic PPI should be considered for trial of de-prescribing, and most patients on twice-daily dosing should be stepped down to once-daily PPI 1
Monitoring recommendations include checking magnesium levels before starting and periodically during long-term therapy, monitoring for signs of renal deterioration, assessing vitamin B12 status after 3+ years of continuous use, and considering iron studies in patients with anemia symptoms 1, 2